Pinder, SE;
Campbell, AF;
Bartlett, JMS;
Marshall, A;
Allen, D;
Falzon, M;
Dunn, JA;
... Stein, RC; + view all
(2017)
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.
British Journal of Cancer
, 116
(7)
pp. 859-863.
10.1038/bjc.2017.28.
Preview |
Text
Pinder_17 BJC -receptors in OPTIMA.pdf - Published Version Download (91kB) | Preview |
Abstract
BACKGROUND: There is limited data on results of central re-testing of samples from patients with invasive breast cancer categorised in their local hospital laboratories as oestrogen receptor (ER) positive and human epidermal growth factor receptor homologue 2 (HER2) negative. METHODS: The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA prelim) was the feasibility phase of a randomised controlled trial to validate the use of multiparameter assay-directed chemotherapy decisions in the UK National Health Service (NHS). Eligibility criteria included ER positivity and HER2 negativity. Central re-testing of receptor status was mandatory. RESULTS: Of the 431 patients tested centrally, discrepant results between central and local laboratory results were identified in only 19 (4.4%; 95% confidence interval 2.5–6.3%) patients (with 21 tumours). On central review, seven patients had cancers that were ER-negative (1.6%) and 13 (3.0%) patients with 15 tumours had HER2-positive disease, including one tumour discrepant for both biomarkers. CONCLUSIONS: Central re-testing of receptor status of invasive breast cancers in the UK NHS setting shows a high level of reproducibility in categorising tumours as ER-positive and HER2-negative, and raises questions regarding the cost effectiveness and clinical value of central re-testing in this sub-group of breast cancers in this setting.
| Type: | Article |
|---|---|
| Title: | Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/bjc.2017.28 |
| Publisher version: | http://dx.doi.org/10.1038/bjc.2017.28 |
| Language: | English |
| Additional information: | From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/. |
| Keywords: | Oncology, breast cancer, oestrogen receptor, HER2, HER2 gene amplification, estrogen-receptor, progesterone-receptor, endocrine therapy, recommendations, uk, discordance, concordance, specimens, tamoxifen |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1543449 |
Archive Staff Only
 |
View Item |
